TTP AG is an operational holding company specializing in engineering services for the process industry. The company is the majority shareholder of TRIPLAN AG, an engineering service company with focus on the life science, chemical and petrochemical sectors and a team of 420 engineers.
As of 1 April 2019, TTP AG acquired four subsidiaries in Switzerland, Germany, France and Belgium of the Danish pharma engineering group NNE A/S. The entities, which were formerly known as PHARMAPLAN, have outstanding expertise in pharma and biotech engineering and a blue-chip customer base. In Switzerland in particular, PHARMAPLAN is the unchallenged market leader.
The carve-out transaction is absolutely transformative for TTP AG and provides access to attractive new customers and growth segments. PHARMAPLAN’s local presence, competencies, business areas and value chains are highly complementary to TTP AG’s existing operations within the TRIPLAN Group. TTP AG will manage the four NNE subsidiaries as largely independent companies and plans to revive the PHARMAPLAN brand name, under which the companies were known until 2017.
MP supported TRIPLAN‘s management and board in the development of the company‘s growth and buy & build strategy. Focusing on the DACH region, MP performed a thorough market and target research, identifying and analyzing a number of potentially suitable companies based on relevant parameters.
Building on its deep sector know-how and M&A experience, MP skillfully guided TTP AG through the transaction process with NNE. The team coordinated the various workstreams in a complex carve-out transaction, balancing the information requirements of the individual stakeholders and the need for an expeditious and resource-efficient transaction.
Throughout the process, MP managed communications with the seller to achieve a mutually successful transaction, which created a leading European engineering group for the Pharma, Chemical and Petrochemical industry sectors.